Search Results for: "Clinic Roundup"
-
Clinic Roundup
Acelrx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data that showed its sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met the primary and secondary efficacy endpoints in a placebo-controlled, Phase III studyBioWorld Today | Thursday, May 23, 2013 -
Clinic Roundup
These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013BioWorld Today | Thursday, May 9, 2013 -
Clinic Roundup
The study will include 20 subjects, and top-line data are expected by year-endBioWorld Today | Tuesday, May 7, 2013 -
Clinic Roundup
Top-line data are expected in the fourth quarterBioWorld Today | Friday, May 3, 2013 -
Clinic Roundup
Top-line data from the Phase III program are expected in the first quarter of 2015. (See BioWorld Today, Feb. 7, 2013BioWorld Today | Monday, April 29, 2013 -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpointBioWorld Today | Friday, April 26, 2013 -
Clinic Roundup
Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's diseaseBioWorld Today | Monday, April 22, 2013 -
Clinic Roundup
Alkermes Inc., of Dublin, Ireland, said top-line data from a Phase II study showed that ALKS 5461, a drug in development to treat patients who have an inadequate response to standard therapies for clinical depression, significantly reduced depressive symptoms across a range of standard measures, including the study's primary outcome measure, the Hamilton Depression Rating Scale (p = 0.026), the Montgomery-Asberg Depression Scale (p = 0.004) and the Clinical Global Impression-Severity Scale (pBioWorld Today | Thursday, April 18, 2013 -
Pharma: Clinic Roundup
Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like peptide 1 receptor agonist, to insulin glargine, as measured by the reduction of hemoglobin A1c levels, were met in two studies, AWARD-2 and AWARD-4BioWorld Today | Wednesday, April 17, 2013 -
Clinic Roundup
Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testingBioWorld Today | Thursday, April 4, 2013 -
Clinic Roundup
Theraclone Sciences Inc., of Seattle, reported top-line data from its Phase I trial of TCN-202, a fully human monoclonal antibody, discovered using the firm's I-STAR platform and in development for treating human cytomegalovirus infectionBioWorld Today | Wednesday, April 3, 2013 -
Clinic Roundup
Biodel expects to report top-line data from the trial in the third quarterBioWorld Today | Friday, March 29, 2013 -
Clinic Roundup
Catalyst said it expects to complete enrollment by the end of the fourth quarter and to announce top-line data during the second quarter of 2014BioWorld Today | Thursday, March 28, 2013 -
Clinic Roundup
Top-line data from the 900-patient trial are expected in the second quarterBioWorld Today | Wednesday, March 27, 2013 -
Clinic Roundup
Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., reported positive top-line data from a Phase IIa trial of Xiaflex (collagenase clostridium histolyticum, or CCH) in adhesive capsulitis, commonly known as frozen shoulder syndrome (FSSBioWorld Today | Tuesday, March 26, 2013 -
Clinic Roundup
AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data demonstrating that the first of two pivotal Phase III studies testing its sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met its primary endpoint, which evaluated pain intensity over the 48-hour study period compared to baseline, or Summed Pain Intensity Difference (SPID-48), in patients following major open abdominal surgery...An additional pivotal study is under way, with top-line data expectedBioWorld Today | Wednesday, March 6, 2013 -
Clinic Roundup
Top-line data from the RA study are expected midyearBioWorld Today | Wednesday, February 27, 2013 -
Clinic Roundup
Top-line data are expected in the fourth quarterBioWorld Today | Thursday, February 21, 2013 -
Clinic Roundup
Top-line data are expected during the second half of this yearBioWorld Today | Wednesday, February 20, 2013 -
Clinic Roundup
Vaximm AG, of Basel, Switzerland, said top-line data from its Phase I/II dose-escalation study of oral cancer vaccine VXM01 met key safety and tolerability endpointsBioWorld Today | Friday, February 8, 2013
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.